Related Experiment Video
Updated: Sep 13, 2025
Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
Published on: September 27, 2024
Early Intervention With an Ultrapulse CO2 Fractional Laser for the Treatment of Traumatic Facial Scars in Children: A
Jingjing Xu1,2, Beibei Niu1,2, Jie Zheng1,2
1Department of Plastic and Burn Surgery, Children's Hospital Affiliated to Shandong University, Jinan, Shandong, China.
Background:
Ultrapulse CO2 fractional lasers are increasingly used for scar treatment. However, the optimal timing for the treatment of traumatic facial scars in children is unclear.
Aim:
This retrospective study evaluated the clinical efficacy of ultrapulse CO2 fractional laser treatment for immature facial scars in pediatric patients, with a focus on identifying the optimal timing to achieve the best possible outcomes.
Patients/Methods:
A total of 106 children with traumatic facial scars were divided into three groups according to when laser treatment was started post-procedure: 1 month (Group A), 3 months (Group B), and 6 months (Group C). Three months after two treatments, the therapeutic effects, adverse reactions, and satisfaction of the patients' families were compared between the three groups.
Results:
After two treatments, the Vancouver Scar Scale (VSS) scores were significantly lower than before treatment in all groups (p < 0.001). Pairwise comparisons demonstrated statistically significant differences between Groups A and B, and between Groups A and C (p < 0.001). Adverse reactions were not significantly different among the three groups (p > 0.05). At the follow-up after two treatments, significantly more patients were very satisfied in Group A than in Groups B and C (p < 0.05).
Conclusions:
Early intervention with an ultrapulse CO2 fractional laser can effectively treat traumatic facial scars in children. The clinical effect and patient satisfaction were better with treatment initiated 1 month post procedure than with treatment 3-6 months post procedure. It has few adverse reactions and high safety and is worthy of clinical promotion and application.
